Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

Summary

The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.

Timeline

Start

2009-06-18

Primary completion

2011-02-18

Completion

2011-02-18

Outcome

Missed primary endpoint

registry analysis (unspecified test); Placebo vs ILV-094 100 mg Every 4 Weeks; p = 0.558; Percent Difference -5.9 (95% CI -25.0 to 13.3); Cochran-Mantel-Haenszel NCT00883896 ↗

Drugs

Indications